INTRODUCTION
Infectious diseases continue to impact human morbidity and mortality. The massive explosions of tourism with an estimated 2 billion passengers each year on commercial airlines and rapid globalization have facilitated the spread of disease-causing pathogens from one continent to another at unprecedented rates. According to the World Health Organization, at least 40 new diseases have emerged over the past two decades, at a rate of one or more per year.
Antimicrobial drugs have been instrumental in saving the lives of millions of people worldwide. The effectiveness of many antibiotics is, however, being steadily eroded by the emergence of drug resistant microorganisms [1] with the WHO declaring that antibiotic resistance is amongst the three greatest challenges to human health. About 25000 patients die each year in the EU from infections with multidrug-resistant bacteria according to the European Medicines Agency causing extra healthcare costs and productivity losses of at least EUR 1.5 billion each year. Crucial drug choices for the treatment of common infections by bacteria, viruses, parasites, and fungi are becoming limited and even nonexistent in some cases [2] . This development has not been paralleled by an effective increase in the discovery of new drugs for most pathogens and the rate of new antimicrobials approvals is steadily dropping. The struggle to control infectious diseases, far from being over, has acquired a new poignancy. Novel concepts acting as adjunct to established therapies are urgently needed. 
CYTOKINE IMMUNOMODULATORS
Cytokines, hormone-like polypeptides possessing pleiotropic properties, are crucial in orchestrating the appropriate immune responses critical for the outcome of an infection.
Certain cytokines stimulate the production of other cytokines and interact in synergistic or antagonistic networks enabling manipulation of the host response to enhance overall immunogenicity and direct the nature of the response either toward type 1 or type 2 pathways. 
INTERFERONS AND COMBINATIONS
Interferon (IFN) was the first cytokine to be produced by the recombinant DNA technology. Interferon-alpha (IFN-) is a clinically effective therapy used in a wide range of viral infections besides its application in malignant melanoma, basal cell carcinoma and warts. At present, licensed therapies widely used for treating liver disease caused by HBV include IFN-α, antiviral drugs lamivudine, adefovir and entecavir [8] . Most of these therapies are limited in the clinic by a low response rate, with only a small subset of patients with hepatitis B and around 40% of cases with hepatitis C being responsive to interferon therapy. The major side effects of all interferon therapies include flu-like syndromes, fever, myalgia, headache and fatigue. Hypotension, granulocytopenia, and thrombocytopenia can also occur.
Deleterious effects on central nervous system, particularly at high doses, have been observed.
COLONY-STIMULATING FACTORS
Granulocyte Colony-Stimulating Factor (G-CSF) preparations such as Filgrastim can significantly enhance neutrophil functions. A high proportion of HIV-infected patients has neutropenia, which considerably increases the risk for bacterial and fungal infections.
Filgrastim was granted license extension to cover the treatment of persistent neutropenia at an advanced stage of HIV infection [11] . In one study conducted at 27 European centers on AIDS patients with cytomegalovirus infection, G-CSF (lenograstim) was found to be suitable for the treatment of ganciclovir-induced neutropenia [12] . Recently developed recombinant 8 human G-CSF, pegfilgrastim, has been shown to be associated with a lower risk of neutropenia-related hospitalizations [13] G-CSF and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) are used to reverse leukopenia as adjunctive therapy for HIV-associated infections. The GM-CSF preparation Sargramostim helps overcome defects in neutrophil and macrophage function due to its broad range of effects on lymphocytes, macrophages, neutrophils, and dendritic cells. It enhances the antiretroviral activity of zidovudine and stavudine in macrophages and ameliorates the hematologic side effects of these agents. Multiple deficiencies are involved in the progression of fungal infections in cancer patients with or without neutropenia. Although clinical experience is still limited, G-CSF, GM-CSF, and macrophage colony-stimulating factor show promise as adjuvant therapy for fungal infections.
CHEMOKINES AND CHEMOKINE MODULATORS
CHEMOKINES have been historically regarded as leukocyte chemoattractants capable of regulating cellular trafficking into inflammatory sites. The sobriquet "chemokine" is abbreviated from chemotactic cytokine. The major classes of chemokines are constituted by the CXC or α chemokines, the CC or β chemokines, the C or γ chemokines, and the CX3C chemokines. The nomenclature of the chemokines is based on the spacing of two critical cystine residues near the amino terminus, indicating no (CC) or one (CXC) or three CX3C) aminoacids acids between the first two cysteins near the amino terminus. The chemokine HIV infection can be inhibited by chemokines and chemokine-related molecules that are ligands for receptors that function as coreceptors. Chemokine receptors thus represent important targets for intervention in HIV and search for molecules that have a therapeutic potential as inhibitors of these receptors has been intense [17] . Intervention strategies based on chemokine antagonists that could be useful for the therapy of HIV include receptor-ligand interaction, prevention of the chemokine-glycosaminoglycan interaction, interfering with the signaling pathways that are induced upon receptor activation, and modification of receptor pathways [18] .
TARGETING CCR5 AND CXCR4
The chemokine receptors CXCR4 and CCR5 are the main coreceptors used respectively by the T-cell-tropic (CXCR4-using, X4) and macrophage-tropic (CCR5-using, R5) HIV for cell entry. Several compounds targeting CXCR4 and CCR5 have been advocated recently. The idea for the drug class came from the observation that presence of mutated CCR5 can confer resistance to HIV infection, even after exposure to numerous high-risk sexual partners. Only around 2 percent of Caucasians carry such a mutation. Another potent TNF inhibitor, thalidomide, has been used in trials in HIV patients [22] . More recently, thalidomide and its immunomodulatory imide analogs such as Actimid, Lenalidomide , Pomalidomide and Revlimid, have been used as anti-inflammatory drugs.
Pentoxifylline, a methylxanthine usually used in the treatment of peripheral arterial circulatory disorders, has been shown to inhibit TNF synthesis. Pentoxifylline has been used in HIV for improving certain functions [23] . Currently, clinical trials are ongoing with phosphodiesterase inhibitors and small-molecule inhibitors of TNF-converting enzyme that specifically interrupt the signaling pathways of TNF.
TNF plays an important role in defense against bacterial and viral infections. Consequently, many patients on anti-TNF drug therapy have shown severe infections such as tuberculosis [24] . A variety of other opportunistic fungal infections by Candidia, Aspergillus Pneumocystis, Coccidioides, Histoplasma, have also been reported in patients treated with anti-TNF monoclonals [25] . 
SYNTHETIC IMMUNOMODULATORS
Microbial pathogens possess a variety of evolutionarily conserved structural motifs known as pathogen-associated molecular patterns (PAMPs). These PAMPS are recognized by a family of specific TLRs. Around thirteen TLRs exhibiting distinct ligand specificities have been identified in humans. TLR2 recognizes bacterial peptidoglycan and lipopeptide, TLR3 recognizes double-stranded RNA, TLR4 binds to lipopolysaccharide, TLR5 binds to flagellin that is part of the flagellum that propels many kinds of bacteria. TLR7 and TLR8 recognize imidazoquinoline compounds and single-stranded RNA from viruses, whereasTLR9 binds to unmethylated CpG DNA motifs frequently found in the genome of bacteria and viruses.
In humans, TLR7 and TLR9 are expressed on the plasmacytoid dendritic cells (PDC) which can rapidly synthesize large amounts IFN-and IFN-in response to viral infection.
Interestingly, TLR7 recognizes synthetic immunomodulators such as Imiquimod, a fully synthetic immune response enhancing imidazoquinoline amine [28] , that are used against viral infections. Imiquimod is marketed as Aldara™ for genital warts caused by human papillomavirus (HPV) subtypes number 6 and 11, but is widely used for basal cell carcinoma, 
Defensins
Defensins are polypeptides of the innate immune system produced in response to microbial infection in humans and animals. Recent reports have highlighted the anti-HIV activities of defensins, whose structure and charge resemble portions of the HIV-1 transmembrane envelope glycoprotein gp41. CD8 T cells from long-term non-progressors with HIV infection were found to secrete a cluster of proteins identified as -defensin 1, 2, and 3. A study of seronegative women who were exposed constantly to HIV-1 demonstrated that their CD8 + cells exhibit extensive -defensin production at both peripheral and mucosal levels. Thedefensin expression level in these seronegative women was 10-fold higher than that of control subjects [30] . Likewise, overexpression of -defensins in breast milk results in a low rate of HIV-1 transmission from mother to infant [31] .
HIV induces -defensin-2 and 3 in human oral epithelial cells which exhibit strong anti-HIV activity due to the direct antiviral effect or competition for the chemokine receptors that HIV uses to enter the cell [32] . Mother-to-child transmission of HIV is the main source of pediatric AIDS. There is a significant relationship between genetic variants of -defensin-1 gene, viral load, and mother-to-child transmission of HIV. In mothers, the -52GG genotype is associated with low levels of HIV plasma viremia and a lower risk of maternal HIV transmission [33] .
Defensins are known to exhibit inhibitory activity against several viruses. Alpha-defensins promote uptake of influenza virus by neutrophils and human defensins 5 and 6 are effective in neutralizing influenza virus [34] . The expression of murine -defensin was enhanced in influenza-infected lungs, trachea and nasal mucosa [35] and treatment of cell cultures with human neutrophil peptides soon after infection -resulted in marked inhibition of influenza virus replication and viral protein synthesis [36] . BK virus is a polyomavirus that establishes a lifelong persistence in most humans. Studies have shown that human alpha-defensins can inhibit BKV infection [37] , inhibit adenovirus infection [38] , and -defensins and humandefensin inhibited herpes simplex virus infection [39] .
Synopsis
The conventional treatment of infectious agents is increasingly encountering antimicrobial resistance. This has led to an intense search for novel treatment modalities for infectious diseases including therapeutic use of biologically manufactured cytokines and cytokine 
